GSM is a condition caused by estrogen deficiency in the vulvovaginal and lower urinary tract tissues. Haver explains that this deficiency leads to a thinning of the epithelial lining and shifts in the local microbiome, resulting in symptoms like dryness, painful intercourse (dyspareunia), urinary urgency, and recurrent urinary tract infections. She emphasizes the importance of correctly identifying GSM, as its symptoms are often misdiagnosed as interstitial cystitis, leading to ineffective treatments. The book positions local, low-dose hormone therapy, such as vaginal estradiol or DHEA, as a first-line treatment that can restore tissue health and dramatically improve quality of life. A key takeaway is the need to screen for and treat GSM as soon as symptoms appear, even if menstrual cycles are still present.

MHT is presented as an evidence-based treatment for the hormone-driven symptoms and health risks of perimenopause and menopause. The author primarily focuses on the use of bioidentical hormones, including estradiol, micronized progesterone, and, where appropriate, testosterone. She carefully distinguishes between two primary strategies. The first is a low-dose “supportive” approach, which uses hormones to stabilize the erratic fluctuations of perimenopause and alleviate symptoms without necessarily stopping ovulation. The second is a “suppress and replace” approach using higher-dose contraceptive hormones to provide predictable cycles and birth control.

Haver emphasizes that MHT is not a one-size-fits-all solution; treatment must be individualized based on a woman’s symptoms, goals, and health risks. For example, transdermal estradiol can be highly effective for mood and sleep disturbances, while local estrogen is the standard of care for GSM. The book also provides historical context, explaining how the misinterpretation of the Women’s Health Initiative study led to a decades-long decline in MHT use, depriving a generation of women of its benefits. This history underscores the author’s call for a reevaluation of MHT as a safe and effective option for many women.

The metabolic syndrome of menopause is a concept proposed by Haver to reframe the cluster of metabolic changes that accelerate in midlife. She defines it as a distinct syndrome driven by estrogen loss, characterized by visceral fat accumulation, rising insulin resistance, dyslipidemia (unhealthy cholesterol and triglyceride levels), and an increased risk of hypertension and metabolic dysfunction-associated steatotic liver disease. By naming this phenomenon, the author aims to shift the focus from blaming women’s lifestyle habits to understanding the underlying biological and endocrine changes.

Evidence from large-scale studies like the Study of Women’s Health Across the Nation supports this concept, showing significant negative shifts in LDL cholesterol and other lipids around the final menstrual period. To address this, Haver advocates for a new standard of proactive screening for women in perimenopause, including annual HOMA-IR tests for insulin resistance, advanced lipid panels (ApoB, Lp[a]), body-composition analysis like DEXA scans, and blood-pressure monitoring. The proposed treatment is multi-modal, combining foundational lifestyle changes like resistance training and an anti-inflammatory diet with medical interventions such as MHT and, for some, GLP-1 receptor agonists.

MSM is defined as the interconnected, estrogen-loss-related decline in muscle mass, muscle strength, and joint integrity that produces widespread pain, weakness, and loss of function. Haver adopts this framework to explain why many women experience symptoms that are frequently misdiagnosed as fibromyalgia or dismissed as purely psychological. The biological drivers of MSM include reduced muscle satellite cell activity, decreased mitochondrial efficiency, and increased systemic inflammation, all resulting from the loss of estrogen’s protective effects. By distinguishing MSM from other chronic pain conditions, the author provides a clear path for targeted intervention. The primary strategies for combating MSM are progressive resistance training, adequate dietary protein, and creatine supplementation to help restore lean muscle mass and improve function. This framework also supports considering MHT and testosterone for eligible women to address the underlying hormonal cause, rather than relying solely on pain management.